



































Deprivation of human natural killer cells and antitumor immune response


 

 

New articles in this journal are licensed under a Creative Commons Attribution 3.0 United States License. 

 

 

This journal is published by the University Library System of the University of Pittsburgh as part  

of its D-Scribe Digital Publishing Program and is cosponsored by the University of Pittsburgh Press. 

 

 

 

 

 

 

 
 

 

Deprivation of human natural 

killer cells and antitumor immune 

response 

 

Vyacheslav Ogay1, Aliya 

Sekenova1, Inpyo Choi2 

 
1Laboratory of Stem Cells, National 
Center for Biotechnology, Almaty, 
Kazakhstan; 2Immunotherapy Research 
Center, Korea Research Institute of 
Bioscience and Biotechnology, Daejeon, 
Republic of Korea

 

Vol. 2, Suppl. (2013)   |   ISSN 2166-7403 (online)    

DOI 10.5195/cajgh.2013.98   |   http://cajgh.pitt.edu 

http://www.library.pitt.edu/
http://www.pitt.edu/
http://www.library.pitt.edu/articles/digpubtype/index.html
http://www.upress.pitt.edu/upressIndex.aspx
http://creativecommons.org/licenses/by/3.0/us/


 

 

OGAY 

 

 

This work is licensed under a Creative Commons Attribution 3.0 United States License. 

 

This journal is published by the University Library System of the University of Pittsburgh as part  

of its D-Scribe Digital Publishing Program and is cosponsored by the University of Pittsburgh Press. 

 

Central Asian Journal of Global Health 

Volume 2, Suppl. (2013)  |  ISSN 2166-7403 (online)  |  DOI 10.5195/cajgh.2013.98  |  http://cajgh.pitt.edu 

  

 

Abstract 

Introduction: Cell-based immunotherapy has been given increased attention as a treatment for cancer. Human natural killer 

(NK) cells are resident lymphocyte populations. They exhibit potent antitumor activity without human leukocyte antigen 

matching and without prior antigen exposure. They also are a promising tool for immunotherapy of solid and hematologic 

cancers. However, most cancer patients do not have enough NK cells to induce an effective antitumor immune response. This 

demonstrates a need for a source of NK cells that can supplement the endogenous cell population. 

Material and methods: In this study, we derived induced pluripotent stem cells (iPSCs) from peripheral blood T-lymphocytes 

using Sendai virus vectors. 

Results:  Generated iPSCs exhibited monoclonal T cell receptors (TCR) rearrangement in their genome, a hallmark of mature 

terminally differentiated T cells. These iPSCs were differentiated into NK cells using a two-stage coculture system: iPSCs into 

hematopoietic CD34+ cells with feeder cells M210-B4 (ATCC, USA) and CD34+ cells into mature NK cells with AFT024 cells 

(ATCC, USA). Our results showed that iPSC-derived NK cells expressed CD56, CD16, NKp 44 and NKp 46, possessed high 

cytotoxic activity  and produced high level of interferon-γ. 

Conclusion: Based on our data, derivation of NK cells from induced pluripotent stem cells should be considered in the treatment 

of oncologic diseases.This would allow for the development of cell therapy for cancer using immunologically compatible NK 

cells derived from iPSCs. This may contribute to a more efficient treatment of oncologic diseases in addition to traditional cancer 

treatment. 

Keywords: human natural killer cells, antitumor immune response, oncologic diseases 

 

 

 

http://www.library.pitt.edu/
http://www.pitt.edu/
http://www.library.pitt.edu/articles/digpubtype/index.html
http://www.upress.pitt.edu/upressIndex.aspx

